Related Experiment Video
Updated: May 22, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
Sweet syndrome associated with hydralazine-induced lupus erythematosus
1Department of Dermatology, Emery University, Atlanta, Georgia 30322, USA. tcartee@emory.edu
Abstract:
Sweet syndrome (SS) is a distinctive but poorly understood clinical syndrome, which likely represents an immunologic reaction pattern to a wide range of underlying or preceding conditions, including viral illnesses, inflammatory bowel disease, and malignancies. We report the case of a patient who presented with an acute eruption that was clinically and histologically consistent with SS. The patient also met diagnostic criteria for systemic lupus erythematosus with serositis, stomatitis, positive antinuclear antibody (ANA), and positive anti-double-stranded DNA antibodies. Additionally, positive antihistone antibodies and exposure to hydralazine supported the specific diagnosis of drug-induced lupus erythematosus, and we concluded that his SS was a manifestation of hydralazine-induced lupus. We also briefly review the precedence for this unusual dual diagnosis in the literature.
Related Concept Videos
Antihypertensive Drugs: Potassium-Sparing Diuretics
Hyperosmolar Hyperglycemic State
Nephrotic Syndrome I : Introduction
Hypersensitivity Reactions: Immune-Complex Reactions
Drug Toxicity: Allergic Reactions
Rheumatic Heart Disease I: Introduction
